The Banff 2015 Kidney Meeting Report

Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

A. Loupy, M. Haas, K. Solez, L. Racusen, D. Glotz, D. Seron, B. J. Nankivell, R. B. Colvin, Marjan Afrouzian, E. Akalin, N. Alachkar, S. Bagnasco, J. U. Becker, L. Cornell, C. Drachenberg, D. Dragun, H. de Kort, I. W. Gibson, E. S. Kraus, C. Lefaucheur & 17 others C. Legendre, H. Liapis, T. Muthukumar, V. Nickeleit, B. Orandi, W. Park, M. Rabant, P. Randhawa, E. F. Reed, C. Roufosse, S. V. Seshan, B. Sis, H. K. Singh, C. Schinstock, A. Tambur, A. Zeevi, M. Mengel

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

Original languageEnglish (US)
Pages (from-to)28-41
Number of pages14
JournalAmerican Journal of Transplantation
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Molecular Pathology
Transplants
Kidney
Antibodies
Composite Tissue Allografts
Molecular Diagnostic Techniques
Transcriptome
Genes
Atrophy
Canada
Blood Vessels
Pancreas
Anti-Idiotypic Antibodies
Fibrosis
Clinical Trials
Inflammation
Biopsy

Keywords

  • clinical research/practice
  • kidney transplantation/nephrology
  • organ transplantation in general
  • pathology/histopathology
  • rejection
  • rejection: antibody-mediated (ABMR)
  • rejection: subclinical
  • rejection: T cell mediated (TCMR)
  • translational research/science

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

The Banff 2015 Kidney Meeting Report : Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. / Loupy, A.; Haas, M.; Solez, K.; Racusen, L.; Glotz, D.; Seron, D.; Nankivell, B. J.; Colvin, R. B.; Afrouzian, Marjan; Akalin, E.; Alachkar, N.; Bagnasco, S.; Becker, J. U.; Cornell, L.; Drachenberg, C.; Dragun, D.; de Kort, H.; Gibson, I. W.; Kraus, E. S.; Lefaucheur, C.; Legendre, C.; Liapis, H.; Muthukumar, T.; Nickeleit, V.; Orandi, B.; Park, W.; Rabant, M.; Randhawa, P.; Reed, E. F.; Roufosse, C.; Seshan, S. V.; Sis, B.; Singh, H. K.; Schinstock, C.; Tambur, A.; Zeevi, A.; Mengel, M.

In: American Journal of Transplantation, Vol. 17, No. 1, 01.01.2017, p. 28-41.

Research output: Contribution to journalArticle

Loupy, A, Haas, M, Solez, K, Racusen, L, Glotz, D, Seron, D, Nankivell, BJ, Colvin, RB, Afrouzian, M, Akalin, E, Alachkar, N, Bagnasco, S, Becker, JU, Cornell, L, Drachenberg, C, Dragun, D, de Kort, H, Gibson, IW, Kraus, ES, Lefaucheur, C, Legendre, C, Liapis, H, Muthukumar, T, Nickeleit, V, Orandi, B, Park, W, Rabant, M, Randhawa, P, Reed, EF, Roufosse, C, Seshan, SV, Sis, B, Singh, HK, Schinstock, C, Tambur, A, Zeevi, A & Mengel, M 2017, 'The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology', American Journal of Transplantation, vol. 17, no. 1, pp. 28-41. https://doi.org/10.1111/ajt.14107
Loupy, A. ; Haas, M. ; Solez, K. ; Racusen, L. ; Glotz, D. ; Seron, D. ; Nankivell, B. J. ; Colvin, R. B. ; Afrouzian, Marjan ; Akalin, E. ; Alachkar, N. ; Bagnasco, S. ; Becker, J. U. ; Cornell, L. ; Drachenberg, C. ; Dragun, D. ; de Kort, H. ; Gibson, I. W. ; Kraus, E. S. ; Lefaucheur, C. ; Legendre, C. ; Liapis, H. ; Muthukumar, T. ; Nickeleit, V. ; Orandi, B. ; Park, W. ; Rabant, M. ; Randhawa, P. ; Reed, E. F. ; Roufosse, C. ; Seshan, S. V. ; Sis, B. ; Singh, H. K. ; Schinstock, C. ; Tambur, A. ; Zeevi, A. ; Mengel, M. / The Banff 2015 Kidney Meeting Report : Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. In: American Journal of Transplantation. 2017 ; Vol. 17, No. 1. pp. 28-41.
@article{3adf1282378e4a4889b5c299c294d396,
title = "The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology",
abstract = "The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.",
keywords = "clinical research/practice, kidney transplantation/nephrology, organ transplantation in general, pathology/histopathology, rejection, rejection: antibody-mediated (ABMR), rejection: subclinical, rejection: T cell mediated (TCMR), translational research/science",
author = "A. Loupy and M. Haas and K. Solez and L. Racusen and D. Glotz and D. Seron and Nankivell, {B. J.} and Colvin, {R. B.} and Marjan Afrouzian and E. Akalin and N. Alachkar and S. Bagnasco and Becker, {J. U.} and L. Cornell and C. Drachenberg and D. Dragun and {de Kort}, H. and Gibson, {I. W.} and Kraus, {E. S.} and C. Lefaucheur and C. Legendre and H. Liapis and T. Muthukumar and V. Nickeleit and B. Orandi and W. Park and M. Rabant and P. Randhawa and Reed, {E. F.} and C. Roufosse and Seshan, {S. V.} and B. Sis and Singh, {H. K.} and C. Schinstock and A. Tambur and A. Zeevi and M. Mengel",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/ajt.14107",
language = "English (US)",
volume = "17",
pages = "28--41",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The Banff 2015 Kidney Meeting Report

T2 - Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

AU - Loupy, A.

AU - Haas, M.

AU - Solez, K.

AU - Racusen, L.

AU - Glotz, D.

AU - Seron, D.

AU - Nankivell, B. J.

AU - Colvin, R. B.

AU - Afrouzian, Marjan

AU - Akalin, E.

AU - Alachkar, N.

AU - Bagnasco, S.

AU - Becker, J. U.

AU - Cornell, L.

AU - Drachenberg, C.

AU - Dragun, D.

AU - de Kort, H.

AU - Gibson, I. W.

AU - Kraus, E. S.

AU - Lefaucheur, C.

AU - Legendre, C.

AU - Liapis, H.

AU - Muthukumar, T.

AU - Nickeleit, V.

AU - Orandi, B.

AU - Park, W.

AU - Rabant, M.

AU - Randhawa, P.

AU - Reed, E. F.

AU - Roufosse, C.

AU - Seshan, S. V.

AU - Sis, B.

AU - Singh, H. K.

AU - Schinstock, C.

AU - Tambur, A.

AU - Zeevi, A.

AU - Mengel, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

AB - The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

KW - clinical research/practice

KW - kidney transplantation/nephrology

KW - organ transplantation in general

KW - pathology/histopathology

KW - rejection

KW - rejection: antibody-mediated (ABMR)

KW - rejection: subclinical

KW - rejection: T cell mediated (TCMR)

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85008946348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008946348&partnerID=8YFLogxK

U2 - 10.1111/ajt.14107

DO - 10.1111/ajt.14107

M3 - Article

VL - 17

SP - 28

EP - 41

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -